International Journal of Risk & Safety in Medicine 21 (2009) 171–173
Doctors of Deception: What They Don’t Want You to Know about Shock Treatment, Linda Andre (Rutgers University Press, NJ, USA), 2009, ISBN: 978-0-8135-4441-0, $26.95.
I was asked to complete a book review of Doctors of Deception: What They Don’t Want You to Knowabout Shock Treatment, by Linda Andre. Although I gladly accepted the request, I had misgivings abouta book whose title implied psychiatric malfeasance. I was also concerned because I had, earlier in mycareer, provided electroconvulsive therapy (ECT) to individuals who I believed would benefit from it. Secondly, not unlike other physicians, I am weary and critical of medical-scientific writings by individ-uals whose background is not medical. With that preface, I opened and read this book with skepticismand no small measure of trepidation. What I discovered was something out of the ordinary.
This book is brilliant analysis. It is successful on many levels, including its most important task:
presenting an overview of the history, safety and efficacy of electro-convulsive therapy. The book is alsoa masterpiece of scientific writing. Through her extensive personal and professional research, Andreexplained to me things I had already known about ECT, but with additional clinical facts and exceptionalinsight. She detailed the people and places that have formed the basis for the historical foundations ofECT at the same time that she described the politics and organizations that have continued to promoteECT as a safe and effective modality.
Linda Andre’s work is also a bit frightening. Since I am one of the psychiatrists trained in the Duke
University ECT program mentioned in the book, and am also someone who practiced ECT up until themid 1990s, I experienced firsthand the marketing pitch that Andre rails against. The book made me feelignorant of ECT’s past, and deceived by having virtually none of the information presented in Andre’sbook brought to my attention previously. Therefore, the book made me think carefully: why and how wasit possible that a non-psychiatric professional could present such compelling and rigorously investigatedinformation while admitting that she, not unlike others, suffers from the memory difficulties and othertraumas of her own personal ECT experience? As significantly, why was this information not offeredearlier by someone with extensive clinical experience working in the field?
The book is not an angry, self-absorbed exposé that wallows in self-pity and undocumented findings.
Rather, it is exceptionally articulate, educational and compelling read. Andre chooses her nouns andverbs carefully instead of relying on subjective adjectives and hyperbolic adverbs that might distort herarguments. If it does hurt the marketing efforts and the proponents of ECT – and it may – it does sobecause it takes aim where psychiatry (or any discipline) is most vulnerable: distorted disclosure offaulty science. Andre elucidates her story with the intensity and suspense of a great “who-done-it whenand how” mystery. She propelled me, uncomfortably at times, to anticipate every subsequent chapter. I wanted to know what happened next.
This book also has the ability to play a larger role in scientific discourse which is not otherwise limited
to ECT. Parallels exist – and the author has suggested them in her Epilogue – with other psychiatric thera-peutics. As examples already in the public domain, other investigators have challenged the reliability andstraightforwardness of scientific reporting and marketing of drugs like paroxetine (Paxil, GlaxoSmith-Kline), gabapentin (Neurontin, Pfizer), olanzapine (Zyprexa, Eli Lilly) and fenfluramine/dexfenfluramine
0924-6479/09/$17.00 2009 – IOS Press and the authors. All rights reserved
(Redux and Pondimin, Wyeth). Synonymous with the best of scientific literature, the book provides atemplate that asks as many questions as it answers. It leaves open the door for further study, especiallyin adjacent fields of concern that require further inquiry.
Andre’s analysis demands repetition. For example, have the proponents of transcranial magnetic ther-
apies or implanted vagal nerve stimulators (VNS) for treatment-resistant depression transparently pre-sented the efficacy and safety data underpinning those treatment modalities? Given what the psychiatricscientific community currently knows about the purported misrepresented safety issues (weight gain, hy-perglycemia, hyperprolactinemia, extrapyramidal side-effects and hyperlipidemia) of atypical antipsy-chotics, who will write the treatise to illuminate who knew what and when but failed to adequatelyinform the healthcare industry and the public about questionable therapeutic interventions?
I disagree with the author about one idea. After Andre carefully reveals the history and problems with
ECT and questions the credibility of the medical-psychiatric establishment due to conflicts of interest,she suggests that those who are agents of debate and change may be “unstoppable”. Certainly the dedi-cation she and others demonstrate to a cause bigger than themselves is vital and important to scientificdebate. I applaud and embrace them. But Andre anticipates that the exposure of ECT’s deleterious ef-fects, although it has taken years to happen, will shine similar light on other medical and psychiatrictreatments where risk is under-exposed or under-appreciated. That is possible. However, that hopeful as-sertion may be naïve, since it opposes a complex and richly rewarded system of academic personalitiesand corporate arrogance. Since Andre presents facts to disturb the status quo of those who mis-promoteECT, she should anticipate headwinds from those she exposes.
The words of Benjamin Franklin might provide comparative perspective. The American statesman
We must not in the course of public life expect immediate approbation and immediate grateful ac-knowledgment of our services. But let us persevere through abuse and even injury. The internalsatisfaction of a good conscience is always present, and time will do us justice in the minds of thepeople, even those at present the most prejudiced against us.
Kudos to Andre who, despite obstacles and prejudice, succeeds in making a powerful contribution toscience and humanity in a story skillfully told. Disclosure
Dr. Kruszewski completed training in electroconvulsive therapy (ECT) at a Duke University mini-
fellowship in 1988. Prior to 1996, he treated individuals with ECT. Dr. Kruszewski does not have any cur-rent business or financial arrangements with any pharmaceutical company. Prior to 2001, Dr. Kruszewskiparticipated on the speaker’s bureaus of the following companies: Pfizer, Inc., GlaxoSmithKline, Janssen
(Johnson and Johnson), AstraZeneca, Wallace Labs, Eli Lilly, GE-Amersham Biosciences; and previ-ously served on an Eli Lilly Northeast Advisory Panel (1998). Dr. Kruszewski has been, and continues tobe, directly involved as an expert in olanzapine, gabapentin, sertraline and OxyContin state and federal,individual plaintiff and class action, litigation. An amicus brief was submitted to the US Supreme Courton behalf of Dr. Kruszewski in the matter of Levine v. Wyeth.
Short-Term and Long-Term Effects of Bisoprolol on Chronic Heart Failure Related to Rheumatic Heart Disease and Atrial Fibrillation Maoqin Shu, MD, Ruixia Xi, PhD, Ping Zhang, MD, Guoxiang He, PhD, Zhiyuan Song, MD, Luxiang Chi, MD, and Guoqiang Zhuang, PhD ABSTRACT treatment group showed improved NYHA class and exercise Objective: We investigated whether a selective beta block
Livro de Ester Situação. Sonho de Mardoqueu 1 Foi no tempo de Assuero, que reinou desde a Índia até a Etiópia sobre cento e vinte e sete províncias. {No segundo ano do reinado de Artaxerxes, o grande rei, no primeiro dia do mês de Nisã, Mardoqueu, filho de Jair, filho de Semei, filho de Cis, da tribo de Benjamim, que servia na corte real, teve um sonho. O sonho foi este: Aparece